Leukemia & Lymphoma最新文献_第10页

Association of comorbidity burden with cause-specific survival after CAR T therapy for large B-cell lymphoma. CAR - T治疗大b细胞淋巴瘤后共病负担与病因特异性生存的关系

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-06-15 DOI: 10.1080/10428194.2026.2682290

Inna Y Gong, Naomi M Xiao, Christine Chen, Sita Bhella, Katrina Hueniken, Massimiliano Marinoni, Maria Azab, Tomohiro Aoki, Robert Kridel, Vishal Kukreti, Abi Vijenthira, Chloe Yang, Danielle Rodin, Meenakshi Jeeva, Mahmood Aminilari, Nauman Malik, Woodrow Wells, David Hodgson, Michael Crump, Anca Prica, John Kuruvilla

引用次数: 0

Efficacy of skin microvasculature C5b-9 and MASP2 deposition in transplant-associated thrombotic microangiopathy. 皮肤微血管C5b-9和MASP2沉积在移植相关血栓性微血管病中的作用

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-06-16 DOI: 10.1080/10428194.2026.2683851

Michael Daunov, John Sumodi, Nikki Agarwal, Molly Gallogly, Leland Metheny, Benjamin Tomlinson, Ali Bseiso, Rebecca Klisovic, Brenda Cooper, Brett Glotzbecker, Kord Honda, Koen van Besien

引用次数: 0

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial. CPX - 351 vs. FLAG - ida在高风险AML/MDS和MDS相关基因突变患者中的应用：英国NCRI AML19试验的亚组分析

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-07-01 DOI: 10.1080/10428194.2026.2690155

Priyanka Mehta, Roderick Murphy, Saemi Park, Stefan Faderl, Tomas Skacel, Abin Thomas, Sean Johnson, Alex Legg

引用次数: 0

The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review. 放疗对CAR - t细胞治疗高级别淋巴瘤患者治疗反应的影响：系统回顾。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-07-16 DOI: 10.1080/10428194.2026.2685253

Maïfa Belghoul, Andrea Kuhnl, Timothy Chevassut, Robin Sanderson, George Mikhaeel, Reuben Benjamin, Piers Patton, John Jones

{"title":"The impact of radiotherapy on the therapeutic response of patients treated with CAR T-cell therapy for high-grade lymphoma: a systematic review.","authors":"Maïfa Belghoul, Andrea Kuhnl, Timothy Chevassut, Robin Sanderson, George Mikhaeel, Reuben Benjamin, Piers Patton, John Jones","doi":"10.1080/10428194.2026.2685253","DOIUrl":"10.1080/10428194.2026.2685253","url":null,"abstract":"Chimeric antigen receptor T (CAR -T) cell therapy is a promising form of cancer treatment with proven efficacy in relapsed/refractory lymphomas. However, there are limitations, including toxicity, failure to achieve immunological memory, and immune evasion. The rationale for administering radiotherapy (RT) with CAR -T, includes increased antigen exposure and immune activation. We studied the current evidence for RT use in high-grade lymphoma patients treated with CD19 CAR-T therapy. The outcomes of interest included progression free survival, complete response rate, overall survival, and incidence of treatment associated toxicities. Five studies were included encompassing 1034 patients. The results indicate that RT is a safe and effective bridging strategy. The combination of RT and CAR-T is associated with improved complete remission rates, but the evidence is limited by cohort heterogeneity and possible selection bias. Further prospective trials are required to confirm this and to determine whether survival outcomes are affected.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2080-2088"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148471457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytomegalovirus reactivation associated with CD20 × CD3 bispecific T-cell engagers: a frequentist and Bayesian analysis of a large national database. 巨细胞病毒再激活与CD20 × CD3双特异性t细胞接触者相关：一个大型国家数据库的频率分析和贝叶斯分析

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-05-28 DOI: 10.1080/10428194.2026.2675498

Connor Frey

引用次数: 0

Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study. 一线套细胞淋巴瘤护理的显著差异——澳大利亚淋巴瘤和相关疾病登记处的一项研究

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-05-26 DOI: 10.1080/10428194.2026.2673099

Zoe Loh, Eliza Chung, Cameron Wellard, Stephen Opat, Eliza A Hawkes, Ross Salvaris

{"title":"Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.","authors":"Zoe Loh, Eliza Chung, Cameron Wellard, Stephen Opat, Eliza A Hawkes, Ross Salvaris","doi":"10.1080/10428194.2026.2673099","DOIUrl":"10.1080/10428194.2026.2673099","url":null,"abstract":"Mantle cell lymphoma (MCL) is a rare malignancy with evolving treatment paradigms. We analyzed 323 MCL patients prospectively recruited to the Australasian Binational Lymphoma Registry between January 2016 and February 2025. Median age was 68 years (range 39-95) and 60% (n = 155) were aged ≥65. Sixteen different first-line regimens were documented. Of young patients <65 years, 81% (n = 85/105) received cytarabine-containing chemoimmunotherapy compared to 23% in those over 65 years. Only 48% of older patients received bendamustine-rituximab based regimens. Autologous stem cell transplant (ASCT) was performed in 44% of patients (aged 43-70 years) and 13% received maintenance rituximab (MR). Three-year progression-free survival (PFS) and overall survival (OS) were 54% (95% confidence interval (CI) 45-62) and 68% (59-74), respectively. In those ≤70 years, ASCT was not associated with PFS or OS. This registry analysis highlights considerable variability in upfront MCL therapy with low ASCT and MR use, providing an important benchmark for emerging standards of care in Australia.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1927-1935"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148031921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL. 阿卡拉布替尼和依鲁替尼治疗treatment-naïve CLL/SLL的高血压和治疗失败的时间。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-06-24 DOI: 10.1080/10428194.2026.2687635

Mayur S Narkhede, Sibel Blau, Aaron Peevyhouse, Heather Neuhalfen, Lee Ann Dietz, Chanh Huynh, Svea K Wahlstrom, Anna Teschemaker, Vikram Shetty, George Dranitsaris, Daniel Ermann

{"title":"Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.","authors":"Mayur S Narkhede, Sibel Blau, Aaron Peevyhouse, Heather Neuhalfen, Lee Ann Dietz, Chanh Huynh, Svea K Wahlstrom, Anna Teschemaker, Vikram Shetty, George Dranitsaris, Daniel Ermann","doi":"10.1080/10428194.2026.2687635","DOIUrl":"10.1080/10428194.2026.2687635","url":null,"abstract":"Bruton tyrosine kinase inhibitors (BTKis) are standard therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The second-generation BTKi, acalabrutinib, has similar efficacy but a more favorable cardiovascular toxicity profile than the first-generation BTKi ibrutinib. This retrospective, observational, real-world study used electronic medical records from ONCare Alliance, a network of 32 US community oncology/hematology practices. Adults (N = 454) with treatment-naïve CLL/SLL who initiated acalabrutinib or ibrutinib monotherapy between January 2017 and December 2023 were included (n = 227 per group). Baseline characteristics were well balanced. The primary endpoint was time to new/worsening hypertension; the key secondary endpoint was time to treatment failure (TTF). After a median follow-up of 28 months, acalabrutinib had fewer discontinuations due to intolerability (19.4% vs 46.7%; p<.001), a significantly lower risk of new/worsening hypertension (HR 0.27; 95% CI, 0.14-0.55; p<.001), and prolonged TTF (HR 0.42; 95% CI, 0.31-0.56; p<.001) versus ibrutinib. Sensitivity analyses demonstrated stability in the findings.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2106-2115"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148317947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chimeric antigen receptor T-cell therapy induces complete remission in a patient with concurrent CLL with CNS involvement and multiple sclerosis. 嵌合抗原受体t细胞治疗诱导CLL合并中枢神经系统累及多发性硬化症患者完全缓解。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-06-07 DOI: 10.1080/10428194.2026.2682293

Dermot J Murphy, Siba El Hussein, Angela Applebee, Alissa Thomas, James N Gerson

引用次数: 0

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population. 与年龄和性别匹配的普通人群相比，venetoclax-obinutuzumab治疗的慢性淋巴细胞白血病患者的总生存率

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-06-25 DOI: 10.1080/10428194.2026.2687633

Lauren D Pomerantz, Kari G Rabe, Paul J Hampel, Lindsey E Roeker, Rachel J Bailen, Amber B Koehler, Catherine C Wagner, Amy L Behnken, Jose F Leis, Talal Hilal, Mazie Tsang, Ricardo D Parrondo, Susan M Schwager, Cinthya J Zepeda-Mendoza, Min Shi, Curtis A Hanson, Susan L Slager, Esteban Braggio, Saad J Kenderian, Neil E Kay, Yucai Wang, Sameer A Parikh

引用次数: 0

Philadelphia-negative B-cell acute lymphoblastic leukemia developing after treatment for multiple myeloma: a case report. 多发性骨髓瘤治疗后发生费城阴性b细胞急性淋巴细胞白血病1例报告。

IF 2.1 4区医学

Leukemia & Lymphoma Pub Date : 2026-08-01 Epub Date: 2026-07-22 DOI: 10.1080/10428194.2026.2693916

Chen Glait Santar, Ben-Zion Katz

引用次数: 0